Month: March 2026

The Lovesac Company Reports Fourth Quarter and Fiscal 2026 Financial Results

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

Q4 FY26 Net Sales Increased 2.7% to $248.0 million vs. Q4 FY25 FY26 Net Sales Increased 2.4% to $697.1 million vs. FY25Announces New $40 million Share Repurchase Authorization STAMFORD, Conn., March 26, 2026 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World’s Most Adaptable Couch, today announced financial results for the fourth quarter and full year fiscal 2026, which ended February 1, 2026. Shawn Nelson, Chief Executive Officer, stated, “Fiscal 2026 was a pivotal year for Lovesac. We made substantial progress on our evolution from a product-driven company into a multi-platform, multi-room, lifestyle brand. A brand that we believe can be the most loved home brand in America in short order, and one day,...

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. “We are encouraged by the progress made in 2025, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson’s disease with or without a GBA1 mutation. The promising impact GT-02287 has on the causative biology of Parkinson’s disease has been further elucidated from the analysis of functional and biomarker changes from the Phase 1b study,”...

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company plans to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in Q1 2027 – – Reported positive top-line results from Phase 2 VALIANT trial of verekitug in patients with severe asthma in February 2026, demonstrating significant improvements in asthma exacerbations and lung function – – Presented additional analyses from Phase 2 VIBRANT trial at AAAAI, reinforcing verekitug’s therapeutic potential in CRSwNP – – Strong cash position of $341.5 million expected to fund planned operations through 2027 – WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments...

First Quantum Provides Notice of First Quarter 2026 Results

Written by Customer Service on March 26, 2026. Posted in Public Companies.

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) will release first quarter 2026 financial and operating results on Tuesday, April 28, 2026 after the close of the Toronto Stock Exchange (“TSX”). The Company will host a conference call and webcast to discuss the results on Wednesday, April 29, 2026 at 9:00 am (ET). Conference call and webcast details:Toll-free North America: 1-800-715-9871International: +1-646-307-1963Conference ID: 8111752Webcast: Direct link or on our website A replay of the webcast will be available on the First Quantum website. About First Quantum First Quantum is engaged in the production of copper, nickel and gold, and related activities including exploration and development. The Company has operating mines located in Zambia and Mauritania....

The Lovesac Company Expands Share Repurchase Authorization by $40 Million

Written by Customer Service on March 26, 2026. Posted in Public Companies.

Total Authorized Repurchase Amount Increases to Approximately $54 Million STAMFORD, Conn., March 26, 2026 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that its Board of Directors has authorized the repurchase of up to an additional $40 million of the Company’s outstanding common stock, expanding its existing share repurchase program to approximately $54.1 million. Keith Siegner, Executive Vice President and Chief Financial Officer, stated, “We are pleased to announce the expansion of our share repurchase program, reflecting strong confidence in our business outlook. With a healthy balance sheet, access to meaningful liquidity through our credit facility, and a disciplined plan for fiscal 2027, we are well-positioned to fund...

StorageVault Expands Footprint with Completion of $62.5 Million of Acquisitions of Five Storage Assets

Written by Customer Service on March 26, 2026. Posted in Mergers And Acquisitions.

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault”) (SVI-TSX) is pleased to announce that, further to its December 18, 2025 news release, it has completed the acquisition of five stores (the “Acquisitions”) from four vendor groups, for an aggregate purchase price of $62.5 million. Three of the Acquisitions are arm’s length and two, totaling $42.4 million, are related party acquisitions (the “Related Party Acquisitions”) with Access Self Storage Inc. (“Access”) and its affiliate (together with Access, the “Access Group”) as the vendors. The aggregate purchase price for the Acquisitions was $62.5 million, subject to customary adjustments. The consideration consisted of $2 million of StorageVault common shares at $5.87 per share (the “Payment Shares”), funds on hand, promissory notes and mortgage financing....

VR Completes Bonding Process for NOI Drill Permit for its New Boston Moly-Tungsten-Copper-Silver Porphyry Project in Nevada

Written by Customer Service on March 26, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, March 26, 2026 (GLOBE NEWSWIRE) — VR Resources Limited (“VR” or the “Company”, TSX.V: VRR, FSE: 5VR0; OTCQB: VRRCF) is pleased to announce that it has completed the standard reclamation bonding process with the Nevada Bureau of Land Management (the “BLM”) for its Notice of Intent (“NOI”) drill permit for its New Boston moly-tungsten-copper-silver porphyry project in Nevada. Concrete planning for a spring drill program is now underway. The requisite bonding process was completed within ten business days of the issuance of the NOI drill permit. The reclamation bonding covers eight potential drill sites in the Jeep Mine area in the western part of the polymetallic porphyry system of sheeted and stockwork veins exposed on surface at New Boston over a strike length of between three and four kilometers. All...

Preliminary results for the year ended 31 December 2025

Written by Customer Service on March 26, 2026. Posted in Public Companies.

A year of strategic execution, strong revenue growth and positive Operating EBITDAStrong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved:Revenue growth of 33% to £170.9 million (CC) (FY 2024: £128.8 million) Operating EBITDA profit of £8.1 million (CC) (FY2024: £(15.3) million), driven by revenue growth and increasing focus on operating costs, and including one-off gain from the acquisition of the Durham, North Carolina (NC) facility. Underlying Operating EBITDA CC of £3.3 million, excluding the impact of the Durham, NC facility (the gain, acquisition, integration and site costs).Revenue backlog up c.36% to c.£204 million, a strong indicator of future revenues and continued growth through 2026 and beyond. Contracted value of orders up c.20% YoY to £224 million...

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

Written by Customer Service on March 26, 2026. Posted in Public Companies.

San Antonio Center Cleared to Commence Commercial Sales of Normal Source Plasma State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full Capacity The Center is Structured to Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D; Anticipated to be One of the Largest Centers for Specialty Plasma Collection in the U.S.REHOVOT, Israel and HOBOKEN, N.J., March 26, 2026 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma’s...

Cibus, Inc. Announces Pricing of Public Offering of Class A Common Stock

Written by Customer Service on March 26, 2026. Posted in Public Companies.

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the pricing of an underwritten public offering (the “Offering”) of 6,976,744 shares of its Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”) at a purchase price of $2.15 per share of Class A Common Stock. The Company has also granted the underwriter a 30-day option to purchase up to an additional 1,046,511 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the Offering are to be sold by the Company. The gross proceeds of the Offering will be approximately $15 million (or $17.2 million if the underwriter exercises its option to purchase...

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals